Sterling Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Sterling Capital Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-7,239	Closed	-$83K	–	1002
2014 Q4	$83K	Sell	7,239 -8,613	-54%	-$93.5K	﹤0.01%	901
2014 Q3	$183K	Buy	+15,852	New	+$242K	﹤0.01%	878

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sterling Capital Management's CASC Position: Q1 2015 in Review

Sterling Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2015, closing a stake of 7,239 shares — an estimated $83K sold.

Sterling Capital Management first reported a position in CASC in Q3 2014 and held it in 2 quarters. The position peaked at $183K in Q3 2014. 90 funds tracked by Wall St. Rank hold CASC as of Q1 2015.

Sterling Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Sterling Capital Management sold 7,239 Cascadian Therapeutics, Inc. shares in Q1 2015, an estimated $83K.
Sterling Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 2 quarters.
Sterling Capital Management's Cascadian Therapeutics, Inc. position peaked at $183K in Q3 2014.
90 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2015.

Based on Sterling Capital Management's 13F filing for Q1 2015, filed 19 May 2015.